Feb 28, 2020 07:00AM

Feb 27, 2020 07:00AM

Feb 18, 2020 07:15AM

Feb 18, 2020 07:00AM

Jan 22, 2020 09:03AM

Jan 22, 2020 09:00AM

Dec 4, 2019 07:00AM Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

Nov 7, 2019 07:00AM

Oct 2, 2019 07:00AM

Sep 4, 2019 07:06AM

Sep 4, 2019 07:00AM

Aug 7, 2019 07:00AM

Jun 4, 2019 07:01AM

Jun 4, 2019 07:00AM Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy

May 9, 2019 07:00AM

May 7, 2019 07:28AM

May 7, 2019 07:00AM

Apr 10, 2019 07:41AM

Apr 10, 2019 07:30AM

Apr 9, 2019 07:01AM

Apr 9, 2019 07:00AM Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study

Mar 7, 2019 07:31AM

Dec 11, 2018 09:29AM

Dec 10, 2018 07:01AM

Dec 10, 2018 07:00AM

Nov 7, 2018 04:23PM

Sep 26, 2018 07:32AM

Sep 26, 2018 07:30AM Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment

Sep 5, 2018 07:31AM

Sep 5, 2018 07:30AM

Aug 8, 2018 08:08AM

Aug 8, 2018 07:15AM

Feb 28, 2018 07:00AM

Aug 9, 2017 04:18PM

Jul 31, 2017 07:13AM Ra Pharmaceuticals (RARX) Announces Receipt of Orphan Drug Designation for RA101495 for Treatment of PNH

Jul 31, 2017 07:12AM

Mar 6, 2017 05:00PM

Feb 28, 2017 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All